Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Number of holders
-
31
-
Total 13F principal, excl. options
-
391,715,535
-
Principal change
-
+3,505,500
-
Total reported value, excl. options
-
$242,598,365
-
Value change
-
+$158,207
-
Number of buys
-
9
-
Number of sells
-
6
-
Price
-
$0.5928
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q3 2022
As of 30 Sep 2022 BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 had 37 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $391,715,535 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included ARISTEIA CAPITAL LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, ORBIMED ADVISORS LLC, AVIVA PLC, MACKAY SHIELDS LLC, STATE STREET CORP, WELLS FARGO & COMPANY/MN, CALAMOS ADVISORS LLC, and TFG Asset Management GP Ltd.
This table shows 37 bond principal holders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.